Company Filing History:
Years Active: 1997-1998
Title: Innovations by Poul Kirketerp Andersson
Introduction
Poul Kirketerp Andersson is a notable inventor based in Frederiksberg, Denmark. He has made significant contributions to the field of biotechnology, particularly in the area of immunization and biological containment. With a total of 3 patents, his work has the potential to impact both medical and industrial applications.
Latest Patents
One of his latest patents is a method of immunization using biologically contained bacterial cells. This innovative approach involves immunizing a vertebrate animal, such as a human, with a bacterial host cell that harbors a recombinant replicon. This replicon provides a stochastically expressed cell killing function, ensuring that the cells are biologically contained. The replicon also includes a gene encoding an antigen that is displayed on the outer surface of the host cell, eliciting an immune response from the immunized animal. The antigen comprises one or more epitopes from a pathogenic agent. Another significant patent focuses on biological containment, where a replicon encodes a cell killing function that is expressed under specific conditions in different host cells. This principle can be utilized in the industrial production of biosynthetic products and in the preparation of live vaccines.
Career Highlights
Throughout his career, Poul Kirketerp Andersson has worked with various companies, including Gx Biosystems A/S and Genexpress ApS. His expertise in biotechnology has allowed him to contribute to advancements in the field, particularly in the development of innovative methods for immunization and biological containment.
Collaborations
Poul has collaborated with notable individuals in his field, including So Slashedren Molin and Kenn Axo Gerdes. These collaborations have further enhanced his research and development efforts, leading to impactful innovations.
Conclusion
Poul Kirketerp Andersson's work exemplifies the intersection of biotechnology and innovation. His patents reflect a commitment to advancing methods of immunization and biological containment, which could have far-reaching implications in both medical and industrial contexts.